• Recently, Anthropic, Blackstone, Hellman & Friedman, and Goldman Sachs formed a new AI-native enterprise services firm, while Blackstone also launched the Blackstone Digital Infrastructure Trust data center REIT and committed US$250 million to Anagram Therapeutics via Blackstone Life Sciences.
• Together, these moves highlight Blackstone’s push into AI-enabled infrastructure and life sciences, aligning its capital with long-term technology and healthcare adoption across its portfolio.
• Next, we’ll examine how Blackstone’s new data center REIT could influence the company’s existing investment narrative and future earnings drivers.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Blackstone Investment Narrative Recap

To own Blackstone, you need to believe in its ability to keep growing fee-based assets while managing cycles in real estate, credit, and private markets. The biggest near term swing factor remains fundraising and deployment in a choppy macro backdrop, while key risks center on market volatility and policy uncertainty affecting realizations and valuations. The new AI and life sciences moves are interesting, but they do not materially change those core near term catalysts or risks yet.

The launch of Blackstone Digital Infrastructure Trust, a US$1.7 billion data center REIT IPO focused on income generating, AI oriented facilities, is the clearest link to this AI push. It fits alongside the new Anthropic enterprise AI firm and the Anagram Therapeutics commitment as another example of Blackstone directing capital into digital infrastructure and healthcare, two areas many investors already watch closely as potential contributors to future fee growth and portfolio resilience.

But against those opportunities, investors should also consider the risk that higher rates and volatility slow deal flow and pressure performance fees...

Blackstone's narrative projects $21.5 billion revenue and $10.5 billion earnings by 2028. This requires 16.7% yearly revenue growth and a $7.6 billion earnings increase from $2.9 billion today.

Uncover how Blackstone's forecasts yield a $162.26 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were already penciling in revenue of about US$23.0 billion and earnings near US$11.9 billion by 2029, see AI partnerships and private wealth channels as powerful offsets to fundraising and redemption worries, while others are more cautious about how market, regulatory, and competitive pressures could reshape those expectations, so it is worth comparing these very different views before you decide how this new AI focused news might shift the story.

Explore 7 other fair value estimates on Blackstone - why the stock might be worth 6% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Blackstone research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Blackstone research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Blackstone's overall financial health at a glance.

No Opportunity In Blackstone?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.